Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates
Sagimet Biosciences Inc. (NASDAQ: SGMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne
https://seekingalpha.com/article/4765804-sagimet-biosciences-denifanstat-should-be-worth-more-today [Seeking Alpha]
Sagimet Biosciences Announces Oral Presentation at the MASH Pathogenesis and Therapeutic Approaches Keystone Symposium